The efficacy of narrowband ultraviolet B (UVB) was assessed in 100 consecutive @entity1 with @entity1569 by quantifying disease severity using objective (Psoriasis Area and Severity Index, PASI and Dermatologists Global Assessment, DGA) and subjective (Psoriasis Disability Index, @entity18035 ) measures. The median pretreatment PASI, DGA and @entity18035 were 5.7 (interquartile range, IQR 4.5-8.35), 7 (IQR 6-9) and 42 (IQR 29-63.5), respectively. At 3 month follow-up, the PASI, DGA and @entity18035 had fallen to 2.7 (IQR 1.1-3.5), 3 (IQR 2-5) and 30 (IQR 21-50.5), respectively (P < 0.001). A small group of @entity1 continued to score highly on their @entity18035 despite being clinically clear or having minimal disease, possibly representing @entity717 behaviour. @entity1 exhibiting this may require more intensive supervision. In most @entity1 , symptoms of itch and @entity158 improved or disappeared (70% and 75%, respectively). Side-effects were reported in 18%. Narrowband UVB phototherapy is safe and effective for @entity1569 . Symptoms and subjective quality of life measures improved significantly. Both objective and subjective measures should be used when evaluating the efficacy of a treatment for @entity1569 .

The efficacy of narrowband ultraviolet B phototherapy in XXXX using objective and subjective outcome measures.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity18035 :: ('5034', 'Gene') :: ['PDI'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity717 :: ('MESH:D009069', 'Disease') :: ['chronic disability']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
